(Total Views: 155)
Posted On: 02/24/2018 6:53:09 PM
Post# of 72441
It's clear that Leo's goal is to find a global licensee for B-OM. First he secured the patents for these countries.
"The European patent supplements other Brilacidin-OM patents that have been granted in the United States, Asia (Japan, Taiwan, China), Oceania (Australia) and South Africa. All currently issued patents have an expiration date of 2032. Additional Brilacidin-OM patent applications are pending in other key markets including Russia and South Korea."
Then he made these comments.
"We are looking at a global product opportunity with OM that is extremely attractive and intellectual property protection is critical."
http://www.ipharminc.com/press-release/2017/1...-mucositis
"This perspective is shared by multiple Pharma companies, potential partners the Company currently is in active discussions with, equally interested in the continued development and eventual market introduction of Brilacidin-OM worldwide ."
http://www.ipharminc.com/press-release/2017/1...hise-value
"The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review."
http://www.ipharminc.com/press-release/2018/1...c-diseases
Regional deal? Whatever you say, Scott.
"The European patent supplements other Brilacidin-OM patents that have been granted in the United States, Asia (Japan, Taiwan, China), Oceania (Australia) and South Africa. All currently issued patents have an expiration date of 2032. Additional Brilacidin-OM patent applications are pending in other key markets including Russia and South Korea."
Then he made these comments.
"We are looking at a global product opportunity with OM that is extremely attractive and intellectual property protection is critical."
http://www.ipharminc.com/press-release/2017/1...-mucositis
"This perspective is shared by multiple Pharma companies, potential partners the Company currently is in active discussions with, equally interested in the continued development and eventual market introduction of Brilacidin-OM worldwide ."
http://www.ipharminc.com/press-release/2017/1...hise-value
"The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review."
http://www.ipharminc.com/press-release/2018/1...c-diseases
Regional deal? Whatever you say, Scott.
(3)
(0)
Scroll down for more posts ▼
